Lupin gets USFDA nod for Cephalexin capsules

Lupin has received US Food and Drug Administration (USFDA) approval for Cephalexin capsules, 250 mg and 500 mg.

According to a release issued by Lupin to the BSE today, this is the company's eighth abbreviated new drug application (ANDA) approval by the USFDA and the third in this financial year.

"The US market for Cephalexin capsules is estimated at $80 million," the release added.